Drug Search Results
More Filters [+]

DFN-15

Alternative Names: dfn-15, dfn15, dfn 15
Latest Update: 2023-01-10
Latest Update Note: Clinical Trial Update

Product Description

DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Based on a faster rate of absorption and increased bioavailability, DFN-15 is being evaluated as an abortive medication for acute treatment in patients with migraine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28748412/)

Mechanisms of Action: COX2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dr. Reddy's Laboratories
Company Location: HYDERABAD K7 500-034
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DFN-15

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Headache Disorders|Migraine Disorders

Phase 2: Headache Disorders|Migraine Disorders|Acute Pain|Migraine with Aura|Migraine without Aura|Hyperalgesia

Phase 1: Healthy Volunteers|Migraine Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HHC-2017-0224

P2

Completed

Migraine Disorders|Hyperalgesia|Migraine without Aura|Migraine with Aura

2019-04-12

DFN-15-CD-010

P2

Completed

Acute Pain

2018-08-20

DFN-15-CD-006

P3

Completed

Migraine Disorders|Headache Disorders

2017-11-01

DFN-15-CD-007

P3

Completed

Headache Disorders|Migraine Disorders

2017-11-01

Recent News Events